Furthermore, we found that sorafenib could induce glutathione peroxidase 4 (GPX4)-dependent ferroptosis in RAB13-knockdown HCC, underscoring its potential as a therapeutic target for HCC. The gene discussed is GPX4; the disease is hepatocellular carcinoma.